VCP Scanner
Stock Screener
Filter stocks with fundamental & technical criteria
Market Themes
Curated industry baskets & thematic leaders
Earnings Hub
Calendar, EPS surprise stats & earnings transcripts
Market News
Real-time market intelligence & AI overviews
Insider Buying
SEC Form 4 corporate insider purchases
LearnAll lessons
Candlestick Patterns44 candles, each on two real charts
Pattern GuidesThe playbooks' setups on real breakouts
GlossaryInvesting terms in plain English
MinerviniVCP SetupsTrend Template
O'NeilCup with HandleFlat BaseDouble BottomCANSLIM Leaders
QullamaggieHigh Tight FlagsFlag BreakoutsEpisodic PivotsMomentum Leaders
KellWedge PopEMA Crossback
LivermorePivotal Points
PatternsFalling Wedge & ChannelBase Breakouts
View All Playbooks...
BreakoutsScanner
FAANG & Tech
AAPL vs MSFTNVDA vs AMDGOOGL vs META
Cloud & Cyber
CRM vs NOWCRWD vs PANWSNOW vs DDOG
Consumer & Auto
TSLA vs FAMZN vs WMTNFLX vs DIS
Finance & Crypto
JPM vs BACV vs MACOIN vs MSTR
Index & ETFs
SPY vs QQQVTI vs VOOSPY vs IWM
Compare Any Stocks...
DCF ValuationCalculate intrinsic value of US stocks
Market ValuationBuffett indicator, CAPE & macro gauges
Total ReturnSee dividends + price return history
DCA CalculatorSimulate recurring buys & compounding
VisualizeInteractive multi-year financial charts
Watchlist
BreakoutsScanner
WatchlistPricing
Ctrl K
Pricing
IRMD
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Analyze deeply. Research with clarity.

Data updated daily

Product

  • Screener
  • Scanner
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • Pricing
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly market insights — free

© 2026 VCP Scanner
AboutPrivacyTermsRefund Policy
Not financial advice. Do your own research.
ScreenerBreakoutsScannerWatchlist
IRMDIRadimed Corporation
$82.31$1.1B
Overview & Tools
OverviewChart Terminal ↗Visualize
Valuation & Forecasts
Valuation ModelsEstimatesDCF Model
Price & Analyst Data
Analyst TargetsPrice History
Financial Statements
Income StatementBalance SheetCash FlowRatios & Margins
Performance
P/E HistoryRevenue HistoryEarnings HistoryDividend HistoryTotal Return
Discovery & Screens
Live BreakoutsStock ScreenerOwnership
HomeStocksIRMDFinancials

IRadimed Corporation (IRMD) Income Statement

14Y historyFree accessUpdated daily

Revenue rose to $24.2M in Q3 2026 with gross margins steady between 74% and 78%, though operating margin of 33.6% and EPS of $0.51 were pressured by a sharp growth slowdown in Q2 2026 to 0.3% year-over-year.

Income StatementBalance SheetCash FlowRatios

IRMD Income Statement

Annual statement

IRMD Income Statement

IRadimed Corporation (IRMD) annual income statement — 14-year revenue, gross profit & net income history

AnnualQuarterly
MetricTTMDec'25Dec'24Dec'23Dec'22Dec'21Dec'20Dec'19Dec'18Dec'17Dec'16Dec'15Dec'14Dec'13Dec'12
Sales/Revenue89.34M83.81M73.24M65.56M53.3M41.81M31.72M38.52M30.44M23.08M32.5M31.59M15.65M11.34M7.69M
Revenue Growth %10.97%14.43%11.71%23%27.47%31.83%-17.65%26.54%31.88%-28.97%2.86%101.84%38.03%47.56%-
Cost of Goods Sold21.88M19.49M16.89M15.4M12.02M9.76M8.14M8.82M7.21M5.57M6.15M5.84M3.4M2.85M2.13M
COGS % of Revenue-23.25%23.06%23.5%22.55%23.35%25.67%22.89%23.69%24.13%18.94%18.49%21.75%25.16%27.66%
Gross Profit67.46M64.32M56.35M50.16M41.28M32.05M23.57M29.7M23.23M17.51M26.34M25.75M12.25M8.49M5.56M
Gross Margin %75.51%76.75%76.94%76.5%77.45%76.65%74.33%77.11%76.31%75.87%81.06%81.51%78.25%74.84%72.34%
Gross Profit Growth %-14.15%12.34%21.5%28.81%35.95%-20.63%27.87%32.64%-33.52%2.28%110.25%44.33%52.66%-
Operating Expenses38.6M38.18M34.39M30.12M25.65M22.23M24.33M21.05M17.22M16.23M15.42M14.24M9.18M5.7M4.13M
OpEx % of Revenue-45.55%46.95%45.95%48.13%53.17%76.71%54.66%56.58%70.3%47.46%45.07%58.66%50.26%53.8%
Selling, General & Admin35.31M35.2M31.55M27.26M23.38M20.33M22.43M19.62M15.71M14.5M14.07M12.48M8.11M4.69M3.48M
SG&A % of Revenue-42%43.08%41.59%43.86%48.61%70.71%50.94%51.6%62.84%43.31%39.49%51.84%41.35%45.29%
Research & Development3.29M2.98M2.83M2.86M2.28M1.91M1.9M1.43M1.52M1.72M1.35M1.76M1.07M1.01M654.07K
R&D % of Revenue-3.55%3.87%4.36%4.27%4.56%6%3.72%4.98%7.46%4.15%5.58%6.83%8.91%8.51%
Other Operating Expenses000000000111.38K32.68K121.39K-48.55K-3.46K7.42K
Operating Income28.86M26.15M21.96M20.04M15.63M9.82M-756.09K8.65M6M1.29M10.92M11.51M3.07M2.79M1.42M
Operating Margin %32.3%31.2%29.99%30.56%29.32%23.48%-2.38%22.45%19.72%5.57%33.6%36.44%19.59%24.58%18.54%
Operating Income Growth %-19.04%9.63%28.21%59.18%1398.48%-108.74%44.03%367.22%-88.23%-5.15%275.52%10%95.64%-
EBITDA30.64M27.31M22.78M20.8M16.3M11.22M582.73K9.89M7.11M2.59M11.17M11.74M3.21M2.93M1.53M
EBITDA Margin %34.29%32.59%31.11%31.73%30.58%26.84%1.84%25.68%23.35%11.24%34.37%37.15%20.54%25.8%19.92%
EBITDA Growth %18.59%19.89%9.53%27.62%45.2%1826.18%-94.11%39.12%174.07%-76.78%-4.85%265.08%9.87%91.14%-
D&A (Non-Cash Add-back)1.25M1.17M817.66K765.18K670.67K1.41M1.34M1.24M1.11M1.31M248.3K223.94K149.06K139.04K106.28K
EBIT30.62M28.36M24.28M21.74M16.18M9.84M-756.09K8.65M6.2M1.4M10.95M11.63M3.02M2.78M1.43M
Net Interest Income002.19M1.86M581.85K34.81K132.19K388.8K238.11K122.58K126.42K148.91K5.7K00
Interest Income002.19M1.86M581.85K34.81K132.19K388.8K238.11K122.58K126.42K148.91K5.7K00
Interest Expense000000000000000
Other Income/Expense2.25M2.21M2.31M1.7M553.1K18.61K139.21K395.91K193.54K111.38K32.68K121.39K-48.55K-3.46K7.42K
Pretax Income31.12M28.36M24.28M21.74M16.18M9.84M-616.88K9.04M6.2M1.4M10.95M11.63M3.02M2.78M1.43M
Pretax Margin %34.83%33.84%33.14%33.16%30.36%23.52%-1.94%23.48%20.36%6.05%33.7%36.83%19.28%24.55%18.63%
Income Tax7.13M5.88M5.04M4.55M3.35M510.82K-1.99M-587.64K-106.14K896.62K3.74M4.1M966.98K846.88K465.98K
Effective Tax Rate %22.92%20.74%20.77%20.91%20.72%5.19%321.92%-6.5%-1.71%64.21%34.13%35.28%32.05%30.42%32.54%
Net Income23.98M22.48M19.23M17.19M12.83M9.33M1.37M9.63M6.3M499.76K7.21M7.53M2.05M1.94M966.09K
Net Margin %26.85%26.82%26.26%26.22%24.07%22.3%4.32%25%20.71%2.17%22.2%23.83%13.1%17.08%12.57%
Net Income Growth %13.21%16.88%11.87%34.02%37.56%581.19%-85.79%52.79%1161.29%-93.07%-4.19%267.25%5.86%100.49%-
Net Income (Continuing)23.98M22.48M19.23M17.19M12.83M9.33M1.37M9.63M6.3M499.76K7.21M7.53M2.05M1.94M966.09K
Discontinued Operations000000000000000
Minority Interest000000000000000
EPS (Diluted)1.861.751.501.351.020.740.110.780.520.040.600.600.200.190.09
EPS Growth %13.33%16.67%11.11%32.35%37.84%572.73%-85.9%50%1200%-93.33%0%200%5.26%104.74%-
EPS (Basic)-1.771.521.361.020.760.110.850.520.050.670.680.230.190.09
Diluted Shares Outstanding12.88M12.85M12.78M12.72M12.64M12.59M12.44M12.28M12.11M11.72M11.99M12.56M10.22M10.42M10.42M
Basic Shares Outstanding12.79M12.72M12.67M12.6M12.56M12.35M12.12M11.28M12.11M10.64M10.82M11M8.74M10.42M10.42M
Dividend Payout Ratio-66.9%71.11%76.91%97.9%----------

Key Metrics

Growth RegimeStable
ProfitabilityStrong
Balance SheetHealthy
Cash FlowStable
Top Statement Risk

Q2 EPS miss

Verified Source

Metrics are mathematically derived from official filings.

SEC 10-K (2026Q3)

Revenue Growth Steady but Decelerating

Based on the reported quarterly figures, IRMD's revenue grew from $17.9M in Q2 2024 to $24.2M in Q3 2026, though year-over-year growth swung sharply, falling to just 0.3% in Q2 2026 before recovering to 14.2% in Q3.

The reported figures suggest a business whose top line is compounding at a healthy mid-teens pace over the longer horizon, yet the Q2 2026 near-stall indicates quarterly growth remains lumpy. This pattern is consistent with large multi-unit hospital orders and distributor timing rather than a smooth recurring-revenue run rate, so investors should monitor whether the Q3 rebound persists. Durability of growth will depend on whether disposable consumption scales with MRI procedure volumes as hardware placements fluctuate.

Gross Margin Structurally Anchored near 75%

Reported gross margins have held in a narrow band of roughly 74% to 78% across the ten quarters, with Q2 2026 at 74.1% and Q3 2026 at 76.3%, consistent with a specialized, high-pricing-power device niche.

A stable gross margin of this magnitude suggests IRMD's proprietary non-magnetic pump architecture supports pricing that is largely insulated from commodity cost swings. The modest compression toward 74% in Q2 2026 may reflect product mix or early launch costs for the 3870 platform, but the data do not isolate the cause. Sustained margins near 76% would indicate the pricing moat is intact, while a persistent drift lower would warrant closer scrutiny of cost inputs.

Operating Leverage Visible but Uneven

Operating margin expanded from 31.6% in Q3 2024 to 33.6% in Q3 2026, though it dipped to 31.2% in Q2 2026, suggesting incremental revenue converts to operating income only partially each quarter.

Operating income of $8.1M on $24.2M revenue in Q3 2026 indicates that opex growth has been broadly contained relative to gross profit growth. However, SG&A stepped up to $9.4M in Q3 2026 against $7.8M in Q3 2024, which suggests overhead is growing alongside revenue rather than diluting from it. Investors should monitor whether the operating margin can hold above 32% as the 3870 launch scales.

Net Margin Tracks Operations Closely

Net margin of 26.9% in Q3 2026 sits near operating margin of 33.6%, and reported diluted EPS of $0.51 versus $0.41 in Q2 2026 indicates net income is moving in line with operating results rather than being driven by non-operating items.

The gap between operating and net margin appears consistent across periods, which suggests a stable tax and non-operating profile rather than one-off gains flattering results. Stock-based compensation of roughly $0.7M to $0.8M per quarter is modest relative to net income, limiting its distortion of reported earnings. The Q2 2026 EPS shortfall versus consensus, however, is best understood as an operating miss rather than an accounting artifact.

Fixed R&D and SG&A Base Carries the Model

R&D spending of $875K in Q3 2026 and SG&A of $9.4M against $24.2M revenue show that overhead, not direct cost of goods, is the dominant cost burden, with COGS of $5.7M representing about 24% of revenue.

The cost profile implies a high fixed-cost base in regulatory, sales, and administrative functions that scales efficiently only if revenue keeps rising. R&D has fluctuated between roughly $570K and $956K per quarter, which may reflect timing of 3870 development milestones rather than a structural shift in investment intensity. Management's expense discipline appears adequate, though the data do not disclose headcount or program-level detail needed to fully judge it.

Q2 2026 Marks the Earnings Pressure Point

Q2 2026 represents the clearest inflection in the reported history, with revenue falling to $20.5M from $22.0M in Q1 and EPS dropping to $0.41, the lowest in the recent run before a rebound to $0.51 in Q3.

The Q2 2026 decline coincides with the launch period for the next-generation pump, and the reported figures suggest early launch costs or unfavorable mix may have been the proximate drivers, though the filings provided do not confirm this attribution. The rapid Q3 recovery to $24.2M revenue and $0.51 EPS suggests the disruption was transitory rather than structural. Investors should watch whether the recovery is sustained as the new platform matures.

Growth Quality and Margin Sustainability Questioned

Bears would point to the volatile quarterly growth path, including the 0.3% revenue growth in Q2 2026 and the 8.9% EPS decline year over year, as evidence that the recurring-revenue narrative may be overstated relative to hardware timing.

A skeptical reading suggests that the high margins depend on continued placement of hardware and sustained disposable utilization, both of which may be sensitive to hospital capital budgets and procedure volumes that the data do not fully reveal. The maintained forward guidance implies a sharp sequential rebound that warrants scrutiny, since failure to deliver could further pressure the valuation. Investors should monitor whether margins hold near 75% and whether the 3870 transition proves smoother than the Q2 2026 results indicate.

IRMD — Frequently Asked Questions

Quick answers to the most common questions about buying IRMD stock.

What was IRadimed Corporation's (IRMD) revenue in 2025?

For fiscal year 2025, IRadimed Corporation (IRMD) reported total revenue of $83.8M. This represents a 990.6% increase compared to $7.7M in 2012.

Is IRadimed Corporation (IRMD) profitable?

IRadimed Corporation (IRMD) is profitable, generating $22.5M in net income for the fiscal year ending 2025 with a net profit margin of 26.8%.

What is IRadimed Corporation's operating profit margin?

IRadimed Corporation (IRMD) reported an operating income of $26.1M, resulting in an operating profit margin of 31.2%. This margin reflects the operational efficiency of the business before interest and taxes.

What is IRadimed Corporation's gross profit and gross margin?

IRadimed Corporation (IRMD) generated $64.3M in gross profit for the year, representing a gross profit margin of 76.7%. This demonstrates the company's core pricing power and production efficiency.